PARIS and ATLANTA – November 29, 2007 – biospace med today announced a new distribution partner for its breakthrough EOS ultra low dose 2D|3D* Xray imager in the Latin America and Caribbean markets. Medika International is a specialized marketer and distributor of high-tech medical equipment and sophisticated medical devices in the areas of radiology, cardiology, urology and critical care. biospace med developed EOS using Nobel Prize-winning patented particle detector technology, which significantly reduces patient radiation exposure.
“The EOS ultra low dose 2D|3D technology was developed based on specific needs identified by the orthopedic and imaging communities,” said Whiyie Sang, president of Medika International. “Introducing this technology to new markets will have a profound impact on patient comfort and safety as well as an equally profound impact for physician efficiency.”
EOS full scan images provide unique insight into balance and posture that can provide valuable surgical planning information and may reduce surgery failure revision rates. It also significantly advances image accuracy through weight bearing images that offer physicians a global view of the entire body and an understanding of the relationships that exist between joints.
For more than 20 years, Medika International has represented many multi- national medical manufacturers from its corporate offices in San Juan, Puerto Rico. Its distribution network spans Puerto Rico, the Caribbean, Mexico and other Latin America markets.
“Medika International is known globally as a trusted partner that generates results in the medical technology market,” said Joe Sardano, biospace med senior vice president of sales for the Americas. “As we work together to introduce EOS to new markets in Latin America and the Caribbean, we are certain the customer experience in these geographies will parallel the professionalism and excellent service standards for which biospace med will become known.”
EOS captures a whole or partial body image in a single scan without the need for any digital stitching – all at a reduced dose. In addition, the system allows simultaneous bi-plane image acquisition (frontal and lateral). Information submitted to FDA in support of biospace med’s marketing application demonstrated up to 10 times reduction in dose when compared with commercially available film systems – without
-more- compromising image quality. EOS can also generate a 3D skeletal reconstruction from the two simultaneously acquired planar images. This product will also feature automatic measurement software designed to calculate a variety of length and angle calculations between individual bones and joints, potentially helping to evaluate global balance and posture.
The 3D Workstation
The company is also developing an advanced workstation for the U.S. market, designed to generate a 3D skeletal reconstruction from the two simultaneous planar images. This planned product will also feature automatic measurement software designed to calculate 2D and 3D clinical parameters for diagnosis and therapy planning. Currently, the 3D workstation is commercially available only in Europe and Canada.
About biospace med biospace med was founded on a unique partnership between a Nobel Prize- winning physicist, engineers, orthopaedic surgeons, and radiologists who have developed a complete orthopaedic imaging solution. The company’s lead product, EOS ultra low dose 2D|3D Xray imager, allows full-body imaging of patients in a weight-bearing position that will enable global assessment of balance and posture. The company has corporate headquarters in Paris and Atlanta with an office in Montreal, and is targeting a $2 billion orthopaedic imaging marketplace. biospace med recently raised $18 million (12 m€) in venture capital financing led by NBGI Ventures (London) and Crédit Agricole Private Equity (Paris). Edmond de Rothschild Investment Partners (Paris) and UFG PE (Paris), current investors in the company, also have subscribed to the current round of financing. Learn more at http://www.biospacemed.com.
*EOS 3D is currently commercially available in Europe and Canada only, and is not part of the current FDA clearance.
